2023-507667-19-00
Completed
Phase 1
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Novartis Pharma AG
- Enrollment
- 24
- Locations
- 11
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (11)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Standard-of-Care Chemotherapy in Patients with Locally Advanced or Metastatic Solid Tumors2022-502615-11-00Genentech Inc., Genentech Inc.35
Recruiting
Phase 1
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients2023-507075-22-00Eurofins Optimed, Perha Pharmaceuticals120
Recruiting
Not Applicable
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal SprayNCT07259538VivaVision Biotech, Inc60
Recruiting
Not Applicable
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001NCT07264569Henan Cancer Hospital42